Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
Sign Up to like & getrecommendations! Published in 2020 at "Pharmaceuticals"
DOI: 10.3390/ph14010003
Abstract: Patients with hepatocellular carcinoma (HCC) face a common type of cancer, which is amongst the most deadly types of cancer worldwide. The therapeutic options range from curative resection or ablation to loco regional therapies in… read more here.
Keywords: hepatocellular carcinoma; immune checkpoint; checkpoint inhibitors; inhibitors hepatocellular ... See more keywords
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Sign Up to like & getrecommendations! Published in 2020 at "Vaccines"
DOI: 10.3390/vaccines8040578
Abstract: Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superiority to sorafenib in a… read more here.
Keywords: hepatocellular carcinoma; checkpoint inhibitors; inhibitors hepatocellular; immunotherapy checkpoint ... See more keywords
Identification and Designing Inhibitors for Hepatocellular Carcinoma by Targeting Claudin-10
Sign Up to like & getrecommendations! Published in 2018 at "Research Journal of Pharmacy and Technology"
DOI: 10.5958/0974-360x.2018.00652.2
Abstract: Claudin(CLDN) family proteins are highly involving in human cancer in lung cancer, hepatocellular carcinoma and breast cancer. Hepatocellular carcinoma is initiated due to dysregulation of CLDN-10. It’s also called as malignant hepatoma, the most well-known… read more here.
Keywords: hepatocellular carcinoma; carcinoma; inhibitors hepatocellular; designing inhibitors ... See more keywords